Article (Scientific journals)
Thirty-day clinical outcomes of the Evolut PRO self-expanding transcatheter aortic valve: the international FORWARD PRO study.
Manoharan, Ganesh; Grube, Eberhard; Van Mieghem, Nicolas M et al.
2020In EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 16 (10), p. 850-857
Peer reviewed
 

Files


Full Text
Manoharan FORWARD PRO 30d EuroIntervention2.pdf
Author postprint (645.95 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Aged; Aged, 80 and over; Aortic Valve/diagnostic imaging/surgery; Aortic Valve Stenosis/diagnostic imaging/surgery; Female; Heart Valve Prosthesis; Humans; Male; Postoperative Complications; Prospective Studies; Prosthesis Design; Transcatheter Aortic Valve Replacement/adverse effects; Treatment Outcome
Abstract :
[en] AIMS: The Evolut PRO is a new transcatheter heart valve with an outer pericardial wrap intended to reduce paravalvular leak and facilitate tissue ingrowth. We aimed to evaluate the clinical performance and safety of the Evolut PRO valve in standard practice. METHODS AND RESULTS: FORWARD PRO is a prospective, multinational, multicentre observational study. Transcatheter aortic valve implantation with the Evolut PRO valve (23, 26, or 29 mm) was attempted in 629 non-consecutive patients from 39 centres from February 2018 to January 2019. The primary endpoint was the rate of all-cause mortality at 30 days compared to a pre-specified performance goal. An independent clinical events committee adjudicated safety endpoints based on VARC-2 definitions. All echocardiograms were centrally assessed by an independent core laboratory (Mayo Clinic, Rochester, MN, USA). Baseline characteristics included mean age 81.7±6.1 years, 61.8% female, STS score 4.7±3.3%, and 33.6% were frail. All-cause mortality at 30 days was 3.2%, which was lower than the pre-specified performance goal of 5.5% (p=0.004). Greater than mild AR was present in 1.8% of patients at discharge. CONCLUSIONS: The FORWARD PRO study confirmed the safety and efficacy of the Evolut PRO transcatheter aortic valve system with an external pericardial wrap. ClinicalTrials.gov Identifier: NCT03417011
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Manoharan, Ganesh;  Regional Cardiology Department, Royal Victoria Hospital, Belfast, United Kingdom.
Grube, Eberhard
Van Mieghem, Nicolas M
Brecker, Stephen
Fiorina, Claudia
Kornowski, Ran
Danenberg, Haim
Ruge, Hendrik
Thiele, Holger
LANCELLOTTI, Patrizio  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Søndergaard, Lars
Tamburino, Corrado
Oh, Jae K
Fan, Yunhua
Windecker, Stephan
More authors (5 more) Less
Language :
English
Title :
Thirty-day clinical outcomes of the Evolut PRO self-expanding transcatheter aortic valve: the international FORWARD PRO study.
Publication date :
20 November 2020
Journal title :
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
eISSN :
1969-6213
Volume :
16
Issue :
10
Pages :
850-857
Peer reviewed :
Peer reviewed
Available on ORBi :
since 24 May 2022

Statistics


Number of views
70 (0 by ULiège)
Number of downloads
151 (0 by ULiège)

Scopus citations®
 
24
Scopus citations®
without self-citations
12
OpenCitations
 
2

Bibliography


Similar publications



Contact ORBi